Teen builds DNA analyzer in bedroom, wins UK young engineer of 2013 award

| | Health Exec | Precision Medicine

A little teasing from peers can inspire genius. Just ask 17-year old Fred Turner, a British dark-haired teen who sought to put an end to speculation that he and his red-haired brother had different fathers.

To end the teasing once and for all, the young innovator spent a year building a polymerase chain reaction (PCR) machine in his bedroom at the relatively low cost of $622. His analyzer succeeded not only in affirming his blood ties to his brother, but earned him the UK young engineer of 2013 award.

The homemade DNA analyzer underscores advances in gene sequencing technology and the falling costs of sequencing a base pair. Turner shares more about his bedroom innovation in the video below.

Fred Turner explains his engineering project

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Radiology Business
ACR shares guidance to help members deal with confusing White House executive orders

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Cardiovascular Business
Philips to sell its emergency care business to private equity firm

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

AI in Healthcare
Nat’l Academy of Medicine sets ‘priorities for action’ as healthcare mulls next moves with AI

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.